<SEC-DOCUMENT>0001193125-25-263543.txt : 20251104
<SEC-HEADER>0001193125-25-263543.hdr.sgml : 20251104
<ACCEPTANCE-DATETIME>20251104071202
ACCESSION NUMBER:		0001193125-25-263543
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20251104
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251104
DATE AS OF CHANGE:		20251104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Taysha Gene Therapies, Inc.
		CENTRAL INDEX KEY:			0001806310
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				843199512
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39536
		FILM NUMBER:		251446430

	BUSINESS ADDRESS:	
		STREET 1:		3000 PEGASUS PARK DRIVE
		STREET 2:		SUITE 1430
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75247
		BUSINESS PHONE:		(214) 612-0000

	MAIL ADDRESS:	
		STREET 1:		3000 PEGASUS PARK DRIVE
		STREET 2:		SUITE 1430
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75247
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d17004d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:tsha="http://tayshagtx.com/20251104" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric id="Hidden_dei_SecurityExchangeName" name="dei:SecurityExchangeName" contextRef="duration_2025-11-04_to_2025-11-04">NASDAQ</ix:nonNumeric> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-326">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-11-04_to_2025-11-04">0001806310</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="tsha-20251104.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-11-04_to_2025-11-04"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001806310</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-11-04</xbrli:startDate> <xbrli:endDate>2025-11-04</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-337">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-11-04_to_2025-11-04" format="ixt:datemonthdayyearen" id="ixv-338">November&#160;4, 2025</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-339">Taysha Gene Therapies, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its Charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-11-04_to_2025-11-04" format="ixt-sec:stateprovnameen" id="ixv-340">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-341">001-39536</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-342">84-3199512</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-343">3000 Pegasus Park Drive</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-344">Suite 1430</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-345">Dallas</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-11-04_to_2025-11-04" format="ixt-sec:stateprovnameen" id="ixv-346">Texas</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-347">75247</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-348">(214)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-349">612-0000</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s Telephone Number, Including Area Code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-11-04_to_2025-11-04" format="ixt-sec:boolballotbox" id="ixv-350">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-11-04_to_2025-11-04" format="ixt-sec:boolballotbox" id="ixv-351">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-11-04_to_2025-11-04" format="ixt-sec:boolballotbox" id="ixv-352">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-11-04_to_2025-11-04" format="ixt-sec:boolballotbox" id="ixv-353">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:35%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:31%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-354">Common Stock, $0.00001 par value</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-355">TSHA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <span style=" -sec-ix-hidden:Hidden_dei_SecurityExchangeName">The Nasdaq Stock Market LLC</span> </td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-11-04_to_2025-11-04" format="ixt-sec:boolballotbox" id="ixv-356">&#9746;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2025-11-04_to_2025-11-04" format="ixt-sec:boolballotbox" id="ixv-357">&#9744;</ix:nonNumeric></p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As previously disclosed, Taysha Gene Therapies, Inc. (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Company</span></span>&#8221;) is party to that certain Sales Agreement, dated October&#160;5, 2021, as amended by that certain Amendment No.&#160;1, dated March&#160;30, 2022 (as so amended, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Sales Agreement</span></span>&#8221;), with Goldman Sachs&#160;&amp; Co. LLC, Wells Fargo Securities, LLC and Leerink Partners LLC, as sales agents (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Sales Agents</span></span>&#8221;). Under the Sales Agreement, the Company may offer and sell, from time to time, through the Sales Agents, shares of its common stock, par value $0.00001 per share (the &#8220;common stock&#8221;), having aggregate sales proceeds of up to $150&#160;million. As of September&#160;30, 2025, the Company had offered and sold shares of common stock with an aggregate offering price of approximately $12&#160;million pursuant to the Sales Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;4, 2025, the Company and Leerink Partners LLC entered into Amendment No.&#160;2 (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Amendment No.</span></span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">&#160;2</span></span>&#8221;) to the Sales Agreement pursuant to which Sales Agreement was terminated solely with respect to Leerink Partners LLC. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, on November&#160;4, 2025, the Company and Goldman Sachs&#160;&amp; Co. LLC and Wells Fargo Securities, LLC, as sales agents (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Remaining Sales Agents</span></span>&#8221;), entered into an amendment to the Sales Agreement (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Amendment No.</span></span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">&#160;3</span></span>&#8221; and, together with the Sales Agreement as amended by Amendment No.&#160;2, the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Amended Sales Agreement</span></span>&#8221;) to provide for an increase in the aggregate offering amount under the Sales Agreement, such that as of November&#160;4, 2025, the Company may offer and sell shares of common stock having an aggregate offering price of up to $212&#160;million under the Amended Sales Agreement. The material terms and conditions of the Sales Agreement otherwise remain unchanged. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sales of the shares of common stock through the Remaining Sales Agents, if any, will be made by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including, without limitation, sales made directly on the Nasdaq Global Select Market or any other existing trading market for its common stock. The Remaining Sales Agents will use commercially reasonable efforts to sell the shares of common stock under the Amended Sales Agreement from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions we may impose). The Company is not obligated to make any sales of shares of common stock under the Amended Sales Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing description of the material terms of the Amended Sales Agreement is qualified in its entirety by reference to the full texts of the Sales Agreement, a copy of which was filed as Exhibit 1.2 to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-260069),</span> filed with the Securities and Exchange Commission on October&#160;5, 2021, and incorporated herein by reference, Amendment No.&#160;1 to the Sales Agreement, a copy of which was filed as Exhibit&#160;10.19 to the Company&#8217;s Annual Report on <span style="white-space:nowrap">Form&#160;10-K</span> (File No.&#160;001-39536), filed with the Securities and Exchange Commission on March&#160;31, 2022, and incorporated herein by reference, and each of Amendment No.&#160;2 and Amendment No.&#160;3, which are attached as Exhibit&#160;1.1 and 1.2 hereto, respectively, and incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form&#160;8-K shall not constitute an offer to sell or the solicitation of an offer to buy the common stock discussed herein, nor shall there be any offer, solicitation, or sale of the common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;2.02</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Results of Operations and Financial Condition. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&#160;4, 2025, the Company reported financial results and business highlights for the quarter ended September&#160;30, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K</span> and is incorporated by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in this Item 2.02 of this Current Report on Form <span style="white-space:nowrap">8-K</span> (including Exhibit 99.1) is being furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Exchange Act</span></span>&#8221;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:10%;vertical-align:top;text-align:left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d17004dex11.htm">Amendment No.&#160;2 to Sales Agreement, dated November&#160;4, 2025, by and between the Company and Leerink Partners LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;1.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d17004dex12.htm">Amendment No.&#160;3 to Sales Agreement, dated November&#160;4, 2025, by and among the Company, Goldman Sachs&#160;&amp; Co. LLC and Wells Fargo Securities, LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d17004dex991.htm">Press Release, dated November&#160;4, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:40%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:13%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:40%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">Taysha Gene Therapies, Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Dated: November&#160;4, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kamran Alam</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Kamran Alam</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d17004dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TAYSHA GENE THERAPIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 2 TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SALES
AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">November&nbsp;4, 2025 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TAYSHA
GENE THERAPIES, INC. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3000 Pegasus Park Drive, Suite 1430 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dallas, Texas 75247 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GOLDMAN SACHS&nbsp;&amp; CO. LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10282 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WELLS FARGO SECURITIES, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30 Hudson Yards </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10001 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>with copies to:</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COOLEY LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 Hudson Yards </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10001 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GOODWIN PROCTER LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New York Times Building </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">620 Eighth Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Re: <U>Amendment
No.</U><U></U><U>&nbsp;2 to Sales Agreement </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is hereby made to that certain Sales Agreement, dated October&nbsp;5, 2021, by and among Taysha Gene Therapies, Inc., a Delaware
corporation (the &#8220;<B><U>Company</U></B>&#8221;), Leerink Partners LLC (formerly known as SVB Securities LLC) (&#8220;<B><U>Leerink</U></B>&#8221;) and Wells Fargo Securities, LLC (&#8220;<B><U>Wells Fargo</U></B>&#8221;), as amended by
Amendment No.&nbsp;1 to Sales Agreement, dated March&nbsp;30, 2022, by and among the Company, Goldman Sachs&nbsp;&amp; Co. LLC (&#8220;<B><U>Goldman</U></B>&#8221;), Wells Fargo and Leerink (&#8220;<B><U>Sales Agreement</U></B>&#8221;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This letter serves as our formal notice of termination of the Sales Agreement solely with respect to Leerink. Pursuant to Section&nbsp;11(c)
of the Sales Agreement, the termination of the Sales Agreement with respect to Leerink will be effective as of the close of business on the date hereof. By signing below, the Company hereby agrees to the termination of the Sales Agreement with
respect to Leerink effective as of the close of business on the date hereof, and permanently and irrevocably waives its right to ten (10)&nbsp;days&#8217; notice pursuant to Section&nbsp;11(c) of the Sales Agreement and any other rights to notice
under the Sales Agreement with respect to such termination with respect to Leerink. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>LEERINK PARTNERS LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Peter Fry</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Peter Fry</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Head of Alternative Equities</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Amendment No.&nbsp;2 to Sales Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Accepted and agreed to as of the date first above written:</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TAYSHA GENE THERAPIES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kamran Alan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kamran Alam</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Amendment No.&nbsp;2 to Sales Agreement] </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.2
<SEQUENCE>3
<FILENAME>d17004dex12.htm
<DESCRIPTION>EX-1.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.2 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TAYSHA GENE THERAPIES, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO. 3 TO </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SALES
AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">November&nbsp;4, 2025 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GOLDMAN
SACHS&nbsp;&amp; CO. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">200 West Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York
10282 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">WELLS FARGO SECURITIES, LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30 Hudson Yards </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10001 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is made to the Sales Agreement, dated October&nbsp;5, 2021, by and among Taysha Gene Therapies, Inc., a Delaware corporation (the
&#8220;<B><U>Company</U></B>&#8221;), Leerink Partners LLC (formerly known as SVB Securities LLC)(&#8220;<B><U>Leerink</U></B>&#8221;) and Wells Fargo Securities, LLC (&#8220;<B><U>Wells Fargo</U></B>&#8221;), as amended by Amendment No.&nbsp;1 to
Sales Agreement, dated March&nbsp;30, 2022, by and among the Company, Goldman Sachs&nbsp;&amp; Co. LLC (&#8220;<B><U>Goldman</U></B>&#8221;), Wells Fargo and Leerink and Amendment No.&nbsp;2 to Sales Agreement, dated November&nbsp;4, 2025, by and
between the Company and Leerink. Such Sales Agreement, as amended to date, is hereinafter referred to as the &#8220;<B><U>Sales Agreement</U></B>.&#8221; Pursuant to the Sales Agreement, the Company agreed, in its sole discretion, to issue and sell,
from time to time, through Goldman and Wells Fargo (each, an &#8220;<B><U>Agent</U></B>&#8221; and together, the &#8220;<B><U>Agents</U></B>&#8221;), as agent and/or principal, shares of common stock, par value $0.00001 per share, of the Company.
All capitalized terms used in this Amendment No.&nbsp;3 to Sales Agreement (this &#8220;<B><U>Amendment</U></B>&#8221;) and not otherwise defined herein shall have the respective meanings assigned to such terms in the Sales Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company and the Agents hereby agree as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">A.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Amendments to Sales Agreement</U>. The Sales Agreement is amended as follows: </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">1. Section&nbsp;1 of the Sales Agreement is hereby amended and restated as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.<U>&nbsp;Issuance and Sale of Shares</U>. The Company agrees that, from time to time during the term of this Agreement, on
the terms and subject to the conditions set forth herein, it may issue and sell through an Agent that the Company has designated as sales agent to sell Placement Shares (as defined below) pursuant to the terms of this Agreement (as of any given
time, the &#8220;<B><U>Designated Agent</U></B>&#8221;) up to $212,000,000 of shares of common stock, $0.00001 par value per share, of the Company (the &#8220;<B><U>Common Stock</U></B>&#8221;), subject to the limitations set forth in
Section&nbsp;5(c) (the &#8220;<B><U>Placement Shares</U></B>&#8221;). Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitation set forth in this Section&nbsp;1 on the aggregate gross
sales price of Placement Shares that may be issued and sold under this Agreement from time to time shall be the sole responsibility of the Company, and that the Agents shall have no obligation in connection with such compliance. The issuance and
sale of Placement Shares through the Designated Agent will be effected pursuant to the Registration Statement (as defined below) to be filed by the Company with the Securities and Exchange Commission (the &#8220;<B><U>Commission</U></B>&#8221;) on
or about the date hereof and to become automatically effective upon the filing thereof, although nothing in this Agreement shall be construed as requiring the Company to issue any Placement Shares. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has prepared and will file, in accordance with the provisions
of the Securities Act of 1933, as amended, and the rules and regulations thereunder (collectively, the &#8220;<B><U>Securities Act</U></B>&#8221;), with the Commission an &#8220;automatic shelf registration statement&#8221; as defined under Rule 405
of the Securities Act (&#8220;<B><U>Rule 405</U></B>&#8221;) on Form <FONT STYLE="white-space:nowrap">S-3ASR,</FONT> which automatic shelf registration statement will become effective under Rule 462(e) of the Securities Act (&#8220;<B><U>Rule
462(e)</U></B>&#8221;), including (a)&nbsp;a base prospectus, relating to certain securities, including the Common Stock, to be issued from time to time by the Company, and which incorporates by reference documents that the Company has filed or will
file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (collectively, the &#8220;<B><U>Exchange Act</U></B>&#8221;), and (b)&nbsp;an <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">at-the-market</FONT></FONT> prospectus specifically relating to the Placement Shares to be issued from time to time pursuant to this Agreement (the &#8220;<B><U>ATM Prospectus</U></B>&#8221;). The Company will furnish to
each Agent, for use by such Agent, copies of the base prospectus included as part of such registration statement at the time it becomes effective, as supplemented by the ATM Prospectus. The Company may file one or more additional registration
statements from time to time that will contain a base prospectus and related prospectus or prospectus supplement, if applicable, with respect to the Placement Shares; <I>provided, however</I>, that Agents are provided with a reasonable opportunity
to review any such registration statement or prospectus. Except where the context otherwise requires, such registration statement, including all documents filed as part thereof or incorporated by reference therein, and including any information
contained in a Prospectus (as defined below) subsequently filed with the Commission pursuant to Rule 424(b) under the Securities Act or deemed to be a part of such registration statement pursuant to Rule 430B or Rule 462(b) under the Securities Act,
or any subsequent registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> filed pursuant to Rule 415(a)(6) under the Securities Act by the Company with respect to any Placement Shares, is herein called the
&#8220;<B><U>Registration Statement</U></B>.&#8221; The base prospectus, including all documents incorporated therein by reference, included in the Registration Statement, as it may be supplemented by the ATM Prospectus, in the form in which such
prospectus and/or ATM Prospectus have most recently been filed by the Company with the Commission pursuant to Rule 424(b) under the Securities Act, together with any &#8220;issuer free writing prospectus&#8221; (as used herein, as defined in Rule
433 under the Securities Act (&#8220;<B><U>Rule 433</U></B>&#8221;)), relating to the Placement Shares that (i)&nbsp;is required to be filed with the Commission by the Company or (ii)&nbsp;is exempt from filing pursuant to Rule 433(d)(5)(i), in each
case, in the form filed or required to be filed with the Commission or, if not required to be filed, in the form retained in the Company&#8217;s records pursuant to Rule 433(g), is herein called the &#8220;<B><U>Prospectus</U></B>.&#8221; For the
avoidance of doubt, any reference to &#8220;Prospectus&#8221; in the Sales Agreement shall be deemed to include the ATM Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any reference herein to the Registration Statement, the ATM Prospectus, the Prospectus or any issuer free writing prospectus
shall be deemed to refer to and include the documents, if any, that are or are deemed to be incorporated by reference therein (the &#8220;<B><U>Incorporated Documents</U></B>&#8221;), including, unless the context otherwise requires, the documents,
if any, filed as exhibits to such Incorporated Documents. Any reference herein to the terms &#8220;amend,&#8221; &#8220;amendment&#8221; or &#8220;supplement&#8221; with respect to the Registration Statement, the ATM Prospectus, the Prospectus or
any issuer free writing prospectus shall be deemed to refer to and include the filing of any document under the Exchange Act on or after the most-recent effective date of the Registration Statement, or the respective dates of the ATM Prospectus,
Prospectus or such issuer free writing prospectus, as the case may be, and incorporated therein by reference. For purposes of this Agreement, all references to the Registration Statement, the Prospectus or any amendment or supplement thereto shall
be deemed to include the most recent copy filed with the Commission pursuant to its Electronic Data Gathering Analysis and Retrieval System or, if applicable, the Interactive Data Electronic Application system when used by the Commission
(collectively, &#8220;<B><U>EDGAR</U></B>&#8221;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">2. Section&nbsp;5(a) of the Sales Agreement is hereby amended and restated as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(a)<U>&nbsp;Settlement of Placement Shares</U>. Unless otherwise specified in the applicable Placement Notice, settlement for sales of
Placement Shares will occur on the first Trading Day following the date on which such sales are made (each, a &#8220;<B><U>Settlement Date</U></B>&#8221;). The amount of proceeds to be delivered to the Company on a Settlement Date against receipt of
the Placement Shares sold (the &#8220;<B><U>Net Proceeds</U></B>&#8221;) will be equal to the aggregate gross sales price received by the Designated </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
Agent at which such Placement Shares were sold, after deduction of (i)&nbsp;the Designated Agent&#8217;s commission, discount or other compensation for such sales payable by the Company pursuant
to Section&nbsp;2 hereof, (ii)&nbsp;any other amounts due and payable by the Company to the Designated Agent hereunder pursuant to Section&nbsp;7(g) hereof and (iii)&nbsp;any transaction fees imposed by any governmental or self-regulatory
organization in respect of such sales. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">3. Section&nbsp;6(a) of the Sales Agreement is hereby amended and restated as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(a) The Company and the transactions contemplated by this Agreement meet the requirements for and comply with the conditions for the use of
Form <FONT STYLE="white-space:nowrap">S-3</FONT> (including General Instructions I.A and I.B.1.) under the Securities Act. The Registration Statement will be an automatic shelf registration statement under Rule 405 and will be filed with the
Commission and become effective under the Securities Act prior to the issuance of any Placement Notices by the Company. At the time the Registration Statement becomes effective, the Company will meet the then-applicable requirements for use of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> (including General Instructions I.A and I.B.1.) under the Securities Act. The Registration Statement meets, and the offering and sale of Placement Shares as contemplated hereby comply with, the requirements of
Rule 415(a)(5) under the Securities Act. Each Agent is named as the agents engaged by the Company in the section entitled &#8220;Plan of Distribution&#8221; in the ATM Prospectus. The Company has not received, and has no notice from the Commission
of, any notice pursuant to Rule 401(g)(2) under the Securities Act objecting to the use of the automatic shelf registration statement form. No stop order of the Commission preventing or suspending the use of the base prospectus, the ATM Prospectus
or the Prospectus, or the effectiveness of the Registration Statement, has been issued, and no proceedings for such purpose are pending before or, to the knowledge of the Company, threatened by the Commission. At the time of the initial filing of
the Registration Statement, the Company paid the required Commission filing fees relating to the securities covered by the Registration Statement, including the Placement Shares that may be sold pursuant to this Agreement, in accordance with Rule
457(r) under the Securities Act. Copies of the Registration Statement, the Prospectus, any such amendments or supplements to any of the foregoing and all Incorporated Documents that were filed with the Commission on or prior to the date of this
Agreement have been delivered, or are available through EDGAR, to the Agents and their counsel; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">4. Section&nbsp;6(h) of the Sales
Agreement is hereby amended and restated as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(h) The Registration Statement, when it becomes effective, will conform, and the
Prospectus and any further amendments or supplements to the Registration Statement and the Prospectus, as of the date of the Prospectus or such amendment or supplement, will conform, in all material respects to the requirements of the Securities Act
and the rules and regulations of the Commission thereunder and do not and will not, as of the applicable effective date as to each part of the Registration Statement, as of the applicable filing date as to the Prospectus and any amendment or
supplement thereto, and as of each Applicable Time, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading; <I>provided, however</I>,
that this representation and warranty shall not apply to any statements or omissions made in reliance upon and in conformity with the Agents&#8217; Information (as defined in Section&nbsp;24); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">5. Section&nbsp;6(aa) of the Sales Agreement is hereby amended and restated as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(aa) Neither the Company nor any director, officer or employee nor, to the knowledge of the Company, any agent, affiliate or representative of
the Company is an individual or entity (&#8220;<B><U>Person</U></B>&#8221;) that is, or is 50% or more owned or otherwise controlled by one or more Persons that are, currently the subject or the target of any sanctions administered or enforced by
the U.S. government, including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury (&#8220;<B><U>OFAC</U></B>&#8221;), or the U.S. Department of State and including, without limitation, the designation as
a &#8220;specially designated national&#8221; or &#8220;blocked person,&#8221; the </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
European Union, His Majesty&#8217;s Treasury, the United Nations Security Council, or other relevant sanctions authority (collectively, &#8220;<B><U>Sanctions</U></B>&#8221;); nor is the Company
located, organized or resident in a country or territory that is the subject or target of comprehensive Sanctions (currently, <FONT STYLE="white-space:nowrap">the&nbsp;so-called&nbsp;Donetsk</FONT> People&#8217;s Republic, <FONT
STYLE="white-space:nowrap">the&nbsp;so-called&nbsp;Luhansk</FONT> People&#8217;s Republic and the Crimea region and <FONT STYLE="white-space:nowrap">the&nbsp;non-government&nbsp;controlled</FONT> areas of the Zaporizhzhia and Kherson Regions of
Ukraine (or any other Covered Region of Ukraine identified pursuant to Executive Order 14065), Russia, Cuba, Iran or North Korea) (each, a &#8220;<B><U>Sanctioned Jurisdiction</U></B>&#8221;), and the Company will not directly or indirectly use the
proceeds of the offering of the Placement Shares hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business
with any person that, at the time of such funding, is the subject or the target of Sanctions or with a Sanctioned Jurisdiction or (ii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in the
transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions; and the Company has not knowingly engaged in and is not now knowingly engaged in, and will not engage in, any dealings or transactions with any individual or entity
that at the time of the dealing or transaction is or was the subject of Sanctions or with a Sanctioned Jurisdiction; the Company is not engaged in, or has not, at any time since April&nbsp;24, 2019, engaged in, any dealings or transactions with or
involving any individual or entity that was or is, as applicable, at the time of such dealing or transaction, the subject or target of Sanctions or with any Sanctioned Jurisdiction; and the Company has instituted, and maintains, policies and
procedures designed to promote and achieve continued compliance with Sanctions; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">6. The following shall be added as new
Section&nbsp;6(ddd), Section&nbsp;6(eee) and Section&nbsp;6(fff) to the Sales Agreement: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(ddd)&nbsp;(i) At the original effectiveness of
the Registration Statement, (ii)&nbsp;at the time of the most recent amendment thereto for the purposes of complying with Section&nbsp;10(a)(3) of the Securities Act (whether such amendment was by post-effective amendment, incorporated report filed
pursuant to Section&nbsp;13 or 15(d) of the Exchange Act or in the form of a prospectus), (iii) at the time the Company or any person acting on its behalf (within the meaning, for this clause only, of Rule 163(c)) made any offer relating to the
Placement Shares in reliance on the exemption of Rule 163, (iv) at the date of this Agreement, and (v)&nbsp;at each Applicable Time, the Company was and is a &#8220;well-known seasoned issuer,&#8221; as defined in Rule 405. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(eee) The Company is an &#8220;experienced issuer,&#8221; as defined in FINRA Rule 5110. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(fff) Neither the Company nor any of its subsidiaries is a &#8220;covered foreign person,&#8221; as that term is defined in 31 C.F.R. &#167;
850.209.&nbsp;Neither the Company nor any of its subsidiaries currently engage, or have plans to engage, directly or indirectly, in a covered activity as defined in 31 C.F.R. 850.208. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">7. Section&nbsp;7(n) of the Sales Agreement is hereby amended and restated as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(n) <U>Legal Opinions</U>. (i)&nbsp;On or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a
certificate pursuant to Section&nbsp;7(m) for which no suspension or waiver is applicable, the Company shall cause to be furnished to the Agents a written opinion of Cooley LLP (&#8220;<B><U>Company Counsel</U></B>&#8221;) or other counsel
satisfactory to the Agents, in form and substance reasonably satisfactory to the Agents and its counsel; and (ii)&nbsp;on or prior to the First Placement Notice Date and on any date which the Company is obligated to deliver a certificate pursuant to
Section&nbsp;7(m) for which no suspension or waiver is applicable, the Company shall cause to be furnished to the Agents a &#8220;negative assurances letter&#8221;&nbsp;of Company Counsel or other counsel satisfactory to the Agents, in form and
substance reasonably satisfactory to the Agents and its counsel. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">8. Section&nbsp;7(o) of the Sales Agreement is hereby amended and restated as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(o) <U>Intellectual Property Opinion</U>. On or prior to the First Placement Notice Date and on any date which the Company is obligated to
deliver a certificate pursuant to Section&nbsp;7(m) for which no suspension or waiver is applicable, the Company shall cause to be furnished to the Agents the written opinion of Fenwick&nbsp;&amp; West LLP, counsel for the Company with respect to
intellectual property matters, or such other intellectual property counsel satisfactory to the Agents (&#8220;<B><U>Intellectual Property Counsel</U></B>&#8221;), in form and substance satisfactory to the Agents and its counsel, dated the date that
the opinion letter is required to be delivered, modified, as necessary, to relate to the Registration Statement and the Prospectus as then amended or supplemented;<I>&nbsp;provided</I>,<I>&nbsp;however</I>, that in lieu of such written opinion for
subsequent Representation Dates, Intellectual Property Counsel may furnish the Agents with a letter to the effect that the Agents may rely on a prior opinion letter delivered by such counsel under this Section&nbsp;7(o) to the same extent as if it
were dated the date of such opinion letter (except that statements in such prior opinion letter shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented at such Representation Date); <I>provided,
further</I>, that any such opinion of Intellectual Property Counsel shall only be on or after the First Placement Notice Date and subsequently no more than once a year with the first delivery of opinions by the Company pursuant to this Agreement
following the filing of the Company&#8217;s annual report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K&nbsp;each</FONT> year. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">9.
Section&nbsp;8(g) of the Sales Agreement is hereby amended and restated as follows </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(g)<U>&nbsp;Agents&#8217; Counsel Legal Opinion</U>.
The Agents shall have received from Goodwin Procter LLP, counsel for the Agents, such opinion or opinions, on or before the date on which the delivery of the Company Counsel legal opinions is required pursuant to Section&nbsp;7(n), with respect to
such matters as the Agents may reasonably require, and the Company shall have furnished to such counsel such documents as they may request to enable them to pass upon such matters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">10. Section&nbsp;7(z) of the Sales Agreement is hereby amended and restated as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(z) <U>WKSI</U>. The Company will promptly notify the Agents if the Company ceases to be a <U>WKSI</U> at any time prior to the completion of
the Agents&#8217; distribution of the Placement Shares pursuant to this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">11. Section&nbsp;7(bb) of the Sales Agreement is
hereby amended and restated as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(bb) <U>Renewal of Registration Statement</U>. If, immediately prior to the third anniversary of
the initial effective date of the Registration Statement (the &#8220;<B><U>Renewal Date</U></B>&#8221;), any of the Placement Shares remain unsold and this Agreement has not been terminated, the Company will, prior to the Renewal Date, file a new
shelf registration statement or, if applicable, an automatic shelf registration statement relating to the Common Stock that may be offered and sold pursuant to this Agreement (which shall include a prospectus reflecting the number or amount of
Placement Shares that may be offered and sold pursuant to this Agreement), in a form satisfactory to the Agents and their counsel, and, if such registration statement is not an automatic shelf registration statement, will use its best efforts to
cause such registration statement to be declared effective within 180 days after the Renewal Date. The Company will take all other reasonable actions necessary or appropriate to permit the public offer and sale of the Placement Shares to continue as
contemplated in the expired registration statement and this Agreement. From and after the effective date thereof, references herein to the &#8220;Registration Statement&#8221; shall include such new shelf registration statement or such new automatic
shelf registration statement, as the case may be. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">12. Section&nbsp;8(a) of the Sales Agreement is hereby amended and restated as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">(a) <U>Registration Statement Effective</U>. The Registration Statement shall be effective upon filing in accordance with Rule 462(e) and
shall be available for all offers and sales of Placement Shares (i)&nbsp;that have been issued pursuant to all prior Placement Notices and (ii)&nbsp;that will be issued pursuant to any Placement Notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">13. Section&nbsp;12 of the Sales Agreement is hereby amended and restated as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">12. <U>Notices</U>. All notices or other communications required or permitted to be given by any party to any other party pursuant to the
terms of this Agreement shall be in writing, unless otherwise specified in this Agreement, and if sent to the Agents, shall be delivered to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goldman Sachs&nbsp;&amp; Co. LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">200 West Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10282 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phone No.: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">866-471-2526</FONT></FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Registration Department </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Wells Fargo Securities, LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">500 West 33rd Street, 14th Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10001 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Equity Syndicate Department and Special Equities Desk </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email:&#8195;<U>David.bohn@wellsfargo.com;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8194;&#8201;<U>donald.ho@wellsfargo.com; josie.callanan@wellsfargo.com;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8194;&#8201;<U>Fernando.A.Escano@wellsfargo.com; Joshua.D.Fraser@wellsfargo.com;</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:18%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#8194;&#8201;<U>kathleen.kelly@wellsfargo.com; Jd.Simons@wellsfargo.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">with a copy (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The New York Times Building </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">620 Eighth Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, NY 10018 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Benjamin K. Marsh, Esq. and Janet Hsueh, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Email: BenjaminMarsh@goodwinlaw.com; <U>JHsueh@goodwinlaw.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">and if to the Company, shall be delivered to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Taysha Gene Therapies, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">3000 Pegasus Park Drive, Suite 1430 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dallas, Texas 75247 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Kamran Alam </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;KAlam@tayshagtx.com</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">with copies (which shall not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">55 Hudson Yards </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">New York, New York 10001 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Divakar Gupta; Madison A. Jones </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:&nbsp;</FONT><U>dgupta@cooley.com; madison.jones@cooley.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Each party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address
for such purpose. Each such notice or other communication shall be deemed given (i)&nbsp;when delivered personally on or before 4:30 P.M., New York City time, on a Business Day, or, if such day is not a Business Day, on the next succeeding Business
Day, (ii)&nbsp;by Electronic Notice as set forth in the next paragraph, (iii)&nbsp;on the next Business Day after timely delivery to a nationally-recognized overnight courier or (iv)&nbsp;on the Business Day actually received if deposited in the
U.S. mail (certified or registered mail, return receipt requested, postage prepaid). For purposes of this Agreement, &#8220;<B><U>Business Day</U></B>&#8221; shall mean any day on which the Nasdaq and commercial banks in the City of New York are
open for business. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">An electronic communication (&#8220;<B><U>Electronic Notice</U></B>&#8221;) shall be deemed
written notice for purposes of this Section&nbsp;12 if sent to the electronic mail address specified by the receiving party in Section&nbsp;12. Electronic Notice shall be deemed received at the time the party sending Electronic Notice receives
actual acknowledgment of receipt from the person whom the notice is sent, other than via auto-reply. Any party receiving Electronic Notice may request and shall be entitled to receive the notice on paper, in a nonelectronic form
(&#8220;<B><U>Nonelectronic Notice</U></B>&#8221;), which shall be sent to the requesting party within 10 days of receipt of the written request for Nonelectronic Notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">14. Schedule 2 of the Sales Agreement is hereby amended and restated as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><U>The Company</U> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Kamran
Alam </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>KAlam@tayshagtx.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><B><U>The Agents</U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Goldman Sachs </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Lyla Bibi
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>lyla.bibi@ny.ibd.email.gs.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Ashley Kaplowitz </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>ashley.kaplowitz@ny.ibd.email.gs.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Brock Ghelfi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Brock.Ghelfi@ny.ibd.email.gs.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Deryk Delahanty </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Deryk.A.Delahanty@ny.ibd.email.gs.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><I>Wells Fargo</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">David Bohn
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>David.bohn@wellsfargo.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Donald Ho </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>donald.ho@wellsfargo.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Josie Callanan </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>josie.callanan@wellsfargo.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Fernando A. Escano </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Fernando.A.Escano@wellsfargo.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Joshua D. Fraser </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Joshua.D.Fraser@wellsfargo.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Kathleen Kelly </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>kathleen.kelly@wellsfargo.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">JD Simons </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><U>Jd.Simons@wellsfargo.com</U> </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">B.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Company will pay reasonable fees and disbursements of counsel to the Agents up to $75,000 in the aggregate
incurred in connection with the execution of this Amendment. For the avoidance of doubt, such reimbursement is in addition to the reasonable fees and disbursements of the Agents&#8217; outside legal counsel provided in Section&nbsp;7(g) of the Sales
Agreement. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">C.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>No Other Amendments; References to Agreement</U>. Except as set forth in <U>Part A</U> above, all the terms
and provisions of the Sales Agreement shall continue in full force and effect. All references to the Sales Agreement in the Sales Agreement or in any other document executed or delivered in connection therewith shall, from the date hereof, be deemed
a reference to the Sales Agreement as amended by this Amendment. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">D.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Counterparts</U>. This Amendment may be executed in two or more counterparts, each of which shall be deemed
an original, but all of which together shall constitute one and the same instrument. Delivery of an executed Amendment by one party to the other may be made by facsimile or electronic transmission. Counterparts may be delivered via facsimile,
electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission
method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">E.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Governing Law</U>. This Amendment shall be governed by, and construed in accordance with, the internal laws
of the State of New York without regard to the principles of conflicts of laws. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">F.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Severability; Waiver</U>. In the event that any one or more of the provisions contained herein, or the
application thereof in any circumstance, is held invalid, illegal or unenforceable as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent that it is valid, legal and
enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid, illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and the
remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Amendment. No implied waiver by a party shall arise in the absence of a waiver in writing signed by such party. No failure or
delay in exercising any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any right, power, or privilege
hereunder. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">G.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Headings</U>. The section headings herein are for convenience only and shall not affect the construction
hereof. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[Remainder of page intentionally left blank.] </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing correctly sets forth the understanding among the Company and each of the
Agents, please so indicate in the space provided below for that purpose, whereupon this Amendment No.&nbsp;3 to Sales Agreement and your acceptance shall constitute a binding agreement among the Company and each of the Agents. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TAYSHA GENE THERAPIES, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kamran Alan</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Kamran Alan</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Chief Financial Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Amendment No.</I><I></I><I>&nbsp;3 to Sales Agreement</I>] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="13%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>Accepted and agreed to as of the date first above written:</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>GOLDMAN SACHS&nbsp;&amp; CO. LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Lyla Bibi Maduri</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Lyla Bibi Maduri</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>WELLS FARGO SECURITIES, LLC</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Bohn</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">David Bohn</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Managing Director</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to Amendment No.</I><I></I><I>&nbsp;3 to Sales Agreement</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d17004dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Taysha Gene Therapies Reports Third Quarter 2025 Financial Results and Provides Corporate Update </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT STYLE="white-space:nowrap">TSHA-102</FONT> granted Breakthrough Therapy designation by FDA </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Finalized FDA alignment on REVEAL pivotal trial protocol and SAP, including <FONT STYLE="white-space:nowrap">6-month</FONT> interim analysis
that may expedite BLA submission, which was enabled by the rigorous developmental milestone evaluation in Part A REVEAL Phase 1/2 trials showing an unprecedented response rate </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Dosing of first patient in REVEAL pivotal trial scheduled for Q4 2025, with enrollment of additional patients expected to continue at
multiple sites this quarter </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Presented new supplemental analysis of Part A REVEAL data reinforcing the broad and consistent,
multi-domain impact of <FONT STYLE="white-space:nowrap">TSHA-102</FONT> on activities of daily living at the CNS Annual Meeting </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I><FONT
STYLE="white-space:nowrap">TSHA-102</FONT> continues to be generally well tolerated with no treatment-related SAEs or DLTs in the 12 patients treated in the Part A REVEAL Phase 1/2 trials as of October 2025&nbsp;data cutoff </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Regained full unencumbered rights to <FONT STYLE="white-space:nowrap">TSHA-102</FONT> Rett syndrome program, enabling Taysha to focus on
driving long-term value with full strategic flexibility and optionality </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>Conference call and webcast today at&nbsp;8:30 AM Eastern
Time </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dallas &#8211; November</B><B></B><B>&nbsp;4, 2025 &#8211;</B> Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a
clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today reported financial results for the third quarter
ended&nbsp;September 30, 2025, and provided a corporate update. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;The progress we&#8217;ve made in the third quarter of 2025 sets the stage for a
potentially transformative period ahead for Taysha. We recently received FDA Breakthrough Therapy designation, which reflects the FDA&#8217;s recognition of the therapeutic potential of <FONT STYLE="white-space:nowrap">TSHA-102</FONT> for
individuals with Rett syndrome, who face a profound unmet need. Additionally, we&#8217;re pleased to have finalized alignment with the FDA on our pivotal trial protocol and SAP, including a <FONT STYLE="white-space:nowrap">six-month</FONT> interim
analysis, which we believe provides a clear opportunity to expedite our BLA submission by at least two quarters,&#8221; said Sean P. Nolan, Chairman and Chief Executive Officer of Taysha. &#8220;With Breakthrough Therapy designation and finalized
FDA alignment, together with our strong balance sheet and regained global rights to <FONT STYLE="white-space:nowrap">TSHA-102,</FONT> we believe we are strongly positioned to initiate our REVEAL pivotal trial and accelerate execution toward BLA
submission. We remain on track to dose the first patient in the REVEAL pivotal trial this quarter and expect additional enrollment to continue at multiple sites this quarter. With an estimated 15,000 to 20,000 patients affected by Rett syndrome
across the&nbsp;U.S., EU and&nbsp;U.K. and compelling clinical data from Part A of our REVEAL trials, we see a significant opportunity to bring an innovative therapy with disease-modifying potential to patients.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Corporate and <FONT STYLE="white-space:nowrap">TSHA-102</FONT> Program Highlights </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>FDA Breakthrough Therapy Designation Granted to <FONT STYLE="white-space:nowrap">TSHA-102.</FONT> </B>The U.S.
Food and Drug Administration&nbsp;(FDA) granted Breakthrough Therapy designation to <FONT STYLE="white-space:nowrap">TSHA-102</FONT> for the treatment of Rett syndrome based on the FDA&#8217;s review of positive clinical evidence from Part A of the
REVEAL Phase 1/2 adolescent/adult and pediatric trials (N=12). </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Finalized FDA Alignment on REVEAL Pivotal Trial Protocol and SAP. </B>Taysha finalized alignment with the FDA
on the REVEAL pivotal trial protocol and statistical analysis plan (SAP) that are intended to support the planned Biologics License Application (BLA) submission for <FONT STYLE="white-space:nowrap">TSHA-102,</FONT> following the resolution of
remaining clinical and statistical queries. Previously aligned upon key trial design elements remain unchanged, including the primary endpoint of response rate, defined as the percentage of patients in the developmental plateau population of Rett
syndrome who gain/regain &#8805; one of the 28 natural history defined developmental milestones, with each patient serving as their own control. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Inclusion of a <FONT STYLE="white-space:nowrap">6-month</FONT> interim analysis that may serve as the basis for
BLA submission was enabled by the rigorous developmental milestone evaluation in Part A of the REVEAL Phase 1/2 trials that demonstrated an unprecedented response rate at 6 months that deepened over time. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Response rate of 33% (5 out of 15 patients) is the minimum threshold for success sufficient to reject the natural
history established null hypothesis of 6.7%. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Presented New Supplemental Data Analysis Supporting <FONT STYLE="white-space:nowrap">TSHA-102</FONT> Clinical
Program.</B> A poster presentation, which is available on the&nbsp;<U>Company&#8217;s website</U>, was delivered at the 54<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>&nbsp;Child Neurology Society&nbsp;(CNS) Annual Meeting to highlight
results from a new supplemental analysis of data from Part A of the REVEAL Phase 1/2 trials (May 2025&nbsp;data cutoff). Results provide supportive evidence of broad and consistent functional skill gains/improvements outside of the natural history
defined developmental milestones that further reinforce <FONT STYLE="white-space:nowrap">TSHA-102&#8217;s</FONT> consistent, multi-domain impact on activities of daily living. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">In addition to the consistent achievement of natural history defined developmental milestones, 100% of patients
(N=10) achieved multiple additional skills/improvements derived from validated, structured efficacy scales, with a total of 22 developmental milestones and 165 additional skills/improvements achieved across the 10 patients <FONT
STYLE="white-space:nowrap">post-TSHA-102.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B><FONT STYLE="white-space:nowrap">TSHA-102</FONT> Continues to be Generally Well
Tolerated.</B><B></B>&nbsp;High dose (1x10<SUP STYLE="font-size:75%; vertical-align:top">15</SUP>&nbsp;total vg) and low dose (5.7x10<SUP STYLE="font-size:75%; vertical-align:top">14</SUP>&nbsp;total vg) of
<FONT STYLE="white-space:nowrap">TSHA-102</FONT> continue to be generally well tolerated with no treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs) in the 12 pediatric, adolescent and adult patients dosed in Part A of
the REVEAL Phase 1/2 trials (October 2025&nbsp;data cutoff). This includes eight patients in the high dose cohort and four patients in the low dose cohort. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Regained Full Rights to <FONT STYLE="white-space:nowrap">TSHA-102</FONT> Rett Syndrome Program.</B> Taysha
regained full rights to its lead <FONT STYLE="white-space:nowrap">TSHA-102</FONT> program in October 2025 following expiration of the 2022 Option Agreement between Astellas and Taysha, which had granted Astellas the exclusive option to enter a
negotiation period to obtain an exclusive license to <FONT STYLE="white-space:nowrap">TSHA-102</FONT> and certain rights with respect to change in control transactions involving Taysha. Taysha now holds unencumbered rights to <FONT
STYLE="white-space:nowrap">TSHA-102,</FONT> which enables the Company to focus on driving long-term value with full strategic flexibility and optionality. </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Strengthened Commercial Leadership. </B>David McNinch was appointed as Taysha&#8217;s Chief Commercial Officer
in September 2025, responsible for the Company&#8217;s commercial function. Mr.&nbsp;McNinch brings over two decades of global commercialization and strategic market development experience across multiple therapeutic areas. Most recently, he served
as Chief Business Officer of Encoded Therapeutics, where he led the commercial and partnering strategy across the company&#8217;s gene therapy portfolio. Mr.&nbsp;McNinch previously held senior commercial leadership roles at Prothena Corp. as well
as InterMune, where he led the launch of Esbriet, the first approved treatment for IPF, and supported the company&#8217;s acquisition by Roche. In his role at Taysha, Mr.&nbsp;McNinch reports to Sean McAuliffe, Taysha&#8217;s Chief Business Officer,
who led the development and execution of the commercial launch of Zolgensma for spinal muscular atrophy, the first approved gene therapy for a monogenic CNS disease. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anticipated Milestones </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Dosing of the first patient in the REVEAL pivotal trial is scheduled for the fourth quarter of 2025, with
enrollment of additional patients expected to continue at multiple sites during the quarter. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Update on longer-term safety and efficacy data from Part A of REVEAL Phase 1/2 trials expected in the first half
of 2026 </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Third Quarter 2025 Financial Highlights </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Research and Development Expenses: </B>Research and development expenses were $25.7&nbsp;million for the three
months ended September&nbsp;30, 2025, compared to $14.9&nbsp;million for the three months ended September&nbsp;30, 2024. The increase was driven by <FONT STYLE="white-space:nowrap">BLA-enabling</FONT> process performance qualification manufacturing
initiatives, REVEAL clinical trial activities and higher compensation expenses as a result of increased headcount during the three months ended September&nbsp;30, 2025. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>General and Administrative Expenses: </B>General and administrative expenses were $8.3&nbsp;million for the
three months ended September&nbsp;30, 2025, compared to $7.9&nbsp;million for the three months ended September&nbsp;30, 2024. The increase of $0.4&nbsp;million was primarily due to debt issuance costs incurred in connection with the refinancing of
the Company&#8217;s existing loan and security agreement with Trinity Capital that are recorded in general and administrative expense under the fair value option and was partially offset by lower legal and professional fees. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Net Loss: </B>Net loss for the three months ended September&nbsp;30, 2025, was $32.7&nbsp;million, or $0.09
per share, compared to a net loss of $25.5&nbsp;million, or $0.10 per share, for the three months ended September&nbsp;30, 2024. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Cash and Cash Equivalents: </B>As of September&nbsp;30, 2025, Taysha had $297.3&nbsp;million in cash and cash
equivalents. The Company expects that its current cash resources will support planned operating expenses and capital requirements into 2028. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conference Call and Webcast Information </B>Taysha management will hold a conference call and webcast today at&nbsp;8:30 a.m. ET to review its financial
and operating results and provide a corporate update. The <FONT STYLE="white-space:nowrap">dial-in</FONT> number for the conference call is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">800-245-3047</FONT></FONT> (U.S./Canada) or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">203-518-9765</FONT></FONT> (international). The conference ID for all callers is TAYSHA. The live webcast and replay may be accessed by visiting Taysha&#8217;s&nbsp;website. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About <FONT STYLE="white-space:nowrap">TSHA-102</FONT> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">TSHA-102</FONT> is a self-complementary intrathecally delivered AAV9 investigational gene transfer therapy in clinical
evaluation for Rett syndrome. Designed as a <FONT STYLE="white-space:nowrap">one-time</FONT> treatment, <FONT STYLE="white-space:nowrap">TSHA-102</FONT> aims to address the genetic root cause of the disease by delivering a functional form
of<I>&nbsp;MECP2</I>&nbsp;to cells in the CNS. <FONT STYLE="white-space:nowrap">TSHA-102</FONT> utilizes a novel miRNA-Responsive Auto-Regulatory Element (miRARE) technology designed to mediate levels of<I>&nbsp;MECP2</I>&nbsp;in the CNS on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cell-by-cell</FONT></FONT> basis without risk of overexpression. <FONT STYLE="white-space:nowrap">TSHA-102</FONT> has received Breakthrough Therapy, Regenerative Medicine Advanced Therapy,
Fast Track and Orphan Drug and Rare Pediatric Disease designations from the FDA, Orphan Drug designation from the&nbsp;European Commission&nbsp;and&nbsp;Innovative Licensing&nbsp;and Access Pathway designation from the Medicines and Healthcare
products Regulatory Agency. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Rett Syndrome </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rett syndrome is a rare neurodevelopmental disorder caused by mutations in the <FONT STYLE="white-space:nowrap">X-linked</FONT> <I>MECP2</I> gene encoding
methyl CpG-binding protein 2 (MeCP2), which is essential for regulating neuronal and synaptic function in the brain. The disorder is characterized by loss of communication and hand function, slowing and/or regression of development, motor and
respiratory impairment, seizures, intellectual disabilities and shortened life expectancy. Rett syndrome progression is divided into four key stages, beginning with early onset stagnation at 6 to 18 months of age followed by rapid regression,
plateau and late motor deterioration. Rett syndrome primarily occurs in females and is one of the most common genetic causes of severe intellectual disability. Currently, there are no approved disease-modifying therapies that treat the genetic root
cause of the disease. Rett syndrome caused by a pathogenic/likely pathogenic <I>MECP2 </I>mutation is estimated to affect between 15,000 and 20,000 patients in the U.S., EU, and U.K. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Taysha Gene Therapies </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taysha Gene Therapies
(Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program
<FONT STYLE="white-space:nowrap">TSHA-102</FONT> is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease.<B> </B>With a singular focus on
developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company&#8217;s management team has proven experience in gene therapy development and
commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit
<U>www.tayshagtx.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as
&#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; &#8220;plans,&#8221; and &#8220;future&#8221; or similar expressions are intended to identify forward-looking statements.
Forward-looking statements include, but are not limited to, statements concerning: the potential of <FONT STYLE="white-space:nowrap">TSHA-102,</FONT> including the reproducibility and durability of any favorable results initially seen in patients
dosed to date in clinical trials, including with respect to functional milestones, to positively impact quality of life and alter the course of disease in the patients Taysha seeks to treat; Taysha&#8217;s research, development and regulatory plans
for <FONT STYLE="white-space:nowrap">TSHA-102,</FONT> including the timing of enrolling and dosing patients, initiating additional trials, reporting data from Taysha&#8217;s clinical trials and making regulatory submissions,
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
communications with feedback from the FDA on the regulatory pathway for <FONT STYLE="white-space:nowrap">TSHA-102;</FONT> the potential for <FONT STYLE="white-space:nowrap">TSHA-102</FONT> to
receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed; Taysha&#8217;s ability to realize the benefits of Breakthrough
Therapy Designation; Taysha&#8217;s ability to drive long-term value for stockholders; and the potential market opportunity for Taysha&#8217;s product candidates and Taysha&#8217;s anticipated cash runway. Forward-looking statements are based on
management&#8217;s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these
forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding Taysha&#8217;s business are described in detail in Taysha&#8217;s
Securities and Exchange Commission (&#8220;SEC&#8221;)&nbsp;filings, including in Taysha&#8217;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the full-year ended&nbsp;December 31, 2024 and Quarterly Report on Form <FONT
STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended&nbsp;September 30, 2025, which are available on the SEC&#8217;s website at&nbsp;<U>www.sec.gov</U>. Additional information will be made available in other filings that Taysha makes from
time to time with the&nbsp;SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Taysha Gene Therapies, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Statements of Operations </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share data)<B> </B> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Three Months</B><br><B>Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>For the Nine Months</B><br><B>Ended September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 1,788</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 4,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 6,311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,676</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,035</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impairment of long-lived assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8212;&#8194;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">34,024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">86,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">77,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Loss from operations</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(34,024</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(25,898</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(82,198</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(71,527</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Other income (expense):</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of warrant liability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(292</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(463</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(67</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Change in fair value of term loan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,534</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,703</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,525</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,354</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,240</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(15</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(80</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(81</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(261</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(44</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,054</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Net loss</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(32,733</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(25,524</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(81,144</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(70,513</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss per common share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.09</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.26</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(0.29</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">353,309,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">267,824,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">307,175,982</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">244,052,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Taysha Gene Therapies, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Condensed Consolidated Balance Sheet Data </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>September&nbsp;30,</B><br><B>2025</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2024</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 297,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 139,036</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">449</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">299,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">142,130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property, plant and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7,463</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">217</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 316,554</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 160,364</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 5,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> 3,592</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deferred revenue</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,485</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28,631</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Term loan, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">50,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">43,942</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease liability, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">17,361</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">97,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">88,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Stockholders&#8217; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock, $0.00001 par value per share; 700,000,000 shares authorized and 273,915,373 issued
and outstanding as of September&nbsp;30, 2025, and 400,000,000 shares authorized and 204,943,306 issued and outstanding as of December&nbsp;31, 2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">903,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">677,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(1,143</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(4,031</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(683,449</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(602,305</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#8217; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">218,989</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71,525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Total liabilities and stockholders&#8217; equity</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 316,554</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B> 160,364</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Company Contact:</B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Hayleigh Collins </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Director, Corporate
Communications and Investor Relations </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Taysha Gene Therapies, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>hcollins@tayshagtx.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Carolyn Hawley </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Inizio Evoke </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Carolyn.hawley@inizioevoke.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>tsha-20251104.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/4/2025 10:00:31 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2025"
  xmlns:tsha="http://tayshagtx.com/20251104"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://tayshagtx.com/20251104"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" namespace="http://xbrl.sec.gov/dei/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2025/naics-2025.xsd" namespace="http://xbrl.sec.gov/naics/2025" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tsha-20251104_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="tsha-20251104_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>tsha-20251104_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/4/2025 10:00:31 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>tsha-20251104_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release 2512 Build:20250722.1 -->
<!-- Creation date: 11/4/2025 10:00:31 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="tsha-20251104.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="24.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 04, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001806310<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov.  04,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Taysha Gene Therapies, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-3199512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3000 Pegasus Park Drive<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dallas<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">612-0000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.00001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TSHA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d17004d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d17004d8k.htm">d17004d8k.htm</File>
    <File>tsha-20251104.xsd</File>
    <File>tsha-20251104_lab.xml</File>
    <File>tsha-20251104_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d17004d8k.htm": {
   "nsprefix": "tsha",
   "nsuri": "http://tayshagtx.com/20251104",
   "dts": {
    "inline": {
     "local": [
      "d17004d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "tsha-20251104.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/naics/2025/naics-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "tsha-20251104_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tsha-20251104_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 3,
    "http://xbrl.sec.gov/dei/2025": 3
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 24
   },
   "report": {
    "R1": {
     "role": "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-11-04_to_2025-11-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d17004d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-11-04_to_2025-11-04",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d17004d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://tayshagtx.com//20251104/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-25-263543-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-263543-xbrl.zip
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M/G\<_+?O.^1Z./+XE(E7I\"\JB0WO# CA-9C\ ]Z?-^I_Z@CDGTXD">EO;B
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M7:<HW=5$GF,"DZ]:[#$&_0&('H+_C_H3F!*Y2?,?,.8(7'P<NXI"A^>@-@@
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M(2<#^95&I4[T1B2*I6=%TM0ZR=+C;/4XO7HSS)XFW7=,<(77#8PGS -%/!=
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M\?PH=DGDSR*.6 8\ZPH']?^/^ =02P,$%     @ @#ED6_L6]1D-*@  7M$
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M &73P">JQPD*B\FMA?>U* %8!\L1##F"K1.C.$J2VAH3%9@Q ^*B$CW1Y$C
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MII(UI+6U0I@A'V)HG[2NRV[TXDJQKY+^W"FD/]&H?GH&%,/-3UD&*;)'K0/
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M\PMJX&*;E'??\'GUA1T,1<?P0&:X+7C3!A$*W<ZU%[O@3)]ID\RA>ENV8NL
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M_+RG)MAKK:U9M_49!2-@H-+S7('9F>T'UT_DMN-9 3G+5T@(/+GTS#1Q/@_
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M FH_,N!V.7SHCP]KQ3E0*T.\8>5C;CF<G<PRC3NT!.*<7I9^S8LK.IY+,HN
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M<<9J %<^BE# @L+0M_+0+<H<N,-72"RA4<%^[R32/0]-6H#4NXX=D-8R_8/
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MH9&.H''3%-(P@LTAQ,'"0^^. ]_#!A4+R0XI=B5#%"_RN?D-7V1Y 3'70]<
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M% L/'%UN@5,=(*N_XQ9(96G<@H;G(.%,[0?OGO]>K>U)PY;H!_YWA?]#SJ,
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MCNARO8G ^NFK\VY)-8RAN.A&H0=_WV)[,5:(]^3FLEVXLGO5VV.I*6N6QC\
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M]8"?M6BC5!)-KI21 #"<!FCJ ..E0VG%PH+9N\L>2E5T#UK]R(8//?,;YK_
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M/#71*.UQXHE=LC0"Y?4K0+E+EC=H!(X>F]Y8J@Q3X]55G1C9JGLZ?#/OJ*=
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M^S6N?K1HV@W4B?#U5R;<;1=3;GT)_BBI)43-K7/#01<X#4)(9&;*D$H[4]E
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M,*2N)3*+2!BZ_MWA!_+'^G0M,@ .5 -IG,<-\NN<\;35J#?.Z^\:C5J\+5)
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M2P$"% ,4    " " .61;'',ZX[T&   F(0  #P              @ 'P%
M9#$W,# T9&5X,3$N:'1M4$L! A0#%     @ @#ED6_L6]1D-*@  7M$   \
M             ( !VAL  &0Q-S P-&1E>#$R+FAT;5!+ 0(4 Q0    ( ( Y
M9%L+?VUIB"4  &1/ 0 0              "  11&  !D,3<P,#1D97@Y.3$N
M:'1M4$L! A0#%     @ @#ED6[RODE ^ P  0@L  !$              ( !
MRFL  '1S:&$M,C R-3$Q,#0N>'-D4$L! A0#%     @ @#ED6\0TQ&&M!@
MHTD  !4              ( !-V\  '1S:&$M,C R-3$Q,#1?;&%B+GAM;%!+
M 0(4 Q0    ( ( Y9%M!Q)^9X 0  /@M   5              "  1=V  !T
J<VAA+3(P,C4Q,3 T7W!R92YX;6Q02P4&      < !P"X 0  *GL

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d17004d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tsha-20251104.xsd" xlink:type="simple"/>
    <context id="duration_2025-11-04_to_2025-11-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001806310</identifier>
        </entity>
        <period>
            <startDate>2025-11-04</startDate>
            <endDate>2025-11-04</endDate>
        </period>
    </context>
    <dei:SecurityExchangeName
      contextRef="duration_2025-11-04_to_2025-11-04"
      id="Hidden_dei_SecurityExchangeName">NASDAQ</dei:SecurityExchangeName>
    <dei:AmendmentFlag contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-326">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-11-04_to_2025-11-04"
      id="Hidden_dei_EntityCentralIndexKey">0001806310</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-337">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-338">2025-11-04</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-339">Taysha Gene Therapies, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-340">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-341">001-39536</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-342">84-3199512</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-343">3000 Pegasus Park Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-344">Suite 1430</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-345">Dallas</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-346">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-347">75247</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-348">(214)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-349">612-0000</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-350">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-351">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-352">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-353">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-354">Common Stock, $0.00001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-355">TSHA</dei:TradingSymbol>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-356">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2025-11-04_to_2025-11-04" id="ixv-357">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
